Formulation approaches to short interfering RNA and MicroRNA: Challenges and implications

Journal of Pharmaceutical Sciences

Volumn 101, Issue 11, 2012, Pages 4046-4066

  Guzman Villanueva, Diana ^a,b   El Sherbiny, Ibrahim M ^a,c,d   Herrera Ruiz, Dea ^b   Vlassov, Alexander V ^e   Smyth, Hugh D C ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

^c ZEWAIL CITY OF SCIENCE AND TECHNOLOGY   (Egypt)

^d Mansoura University   (Egypt)

^e Life Technologies   (United States)

Author keywords

Formulations; polymers; In vivo knockdown; Lipid; MiRNA; Nonviral gene delivery; Oligonucleotides; RNA interference; RNAi; SiRNA; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY CONJUGATE; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; CELL PENETRATING PEPTIDE; CHITOSAN; DOUBLE STRANDED RNA; GAMMA INTERFERON; LENTIVIRUS VECTOR; LIPID; LIPOPLEX; LIPOSOME; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 122; MICRORNA 145; NANOCARRIER; NANOPARTICLE; NANOSPHERE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PARVOVIRUS VECTOR; POLYANION; POLYETHYLENEIMINE; POLYMER; RETROVIRUS VECTOR; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

3' UNTRANSLATED REGION; ALGORITHM; AMYLOIDOSIS; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; ANTIVIRAL ACTIVITY; APOPTOSIS; CELL PROLIFERATION; CHEMICAL MODIFICATION; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; ELECTROPORATION; ENCAPSULATION; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENE SILENCING; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HUMAN; IN VIVO GENE TRANSFER; IONIC STRENGTH; LUNG NON SMALL CELL CANCER; METASTATIC MELANOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PANCREAS CANCER; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

EID: 84866372203     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23300     Document Type: Review

References (168)

1. Gary DJ, Puri N, Won YY. 2007. Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 121:64-73.
2. Pushparaj PN, Melendez AJ. 2006. Short interfering RNA (siRNA) as a novel therapeutic. Clin Exp Pharmacol Physiol 33:504-510.
3. Ji AM, Su D, Che O, Li WS, Sun L, Zhang ZY, Yang B, Xu F. 2009. Functional gene silencing mediated by chitosan/siRNA nanocomplexes. Nanotechnology 20:405103.
4. Urakami T, Oku N. 2007. Current status of siRNA delivery technology and siRNA drug development. Open Drug Deliv J 1:20-27.
5. Schiffelers RM, Woodle MC, Scaria P. 2004. Pharmaceutical prospects for RNA interference. Pharm Res 21:1-7.
6. Guo J, Fisher KA, Darcy R, Cryan JF, O'Driscoll C. 2010. Therapeutic targeting in the silent era: Advances in non-viral siRNA delivery. Mol Biosyst 6:1143-1161.
7. Cong M, Liu YF, He Li. 2009. microRNAs-Powerful repression comes from small RNAs. Sci China C Life Sci 52:323-330.
8. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. 2006. Prospects of RNA interference therapy for cancer. Gene Ther 13:464-477.
9. Sioud M. 2010. Recent advances in small interfering RNA sensing by the immune system. N Biotechnol 27:236-242.
10. Durcan N, Murphy C, Cryan SA. 2008. Inhalable siRNA: Potential as a therapeutic agent in the lungs. Mol Pharm 5:559-566.
11. Deiters A. 2009. Small molecule modifiers of the microRNA and RNA interference pathway. AAPS J 12:51-60.
12. Fabian MR, Sonenberg N, Filipowicz W. 2010. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79:351-379.
13. Mor E, Yuval C, Goldshmit Y, Zalts H, Modai S, Edry L, Elroy-Stein O, Shomron N. 2011. Species-specific microRNA roles elucidated following astrocyte activation. Nucleic Acids Res 39:3710-3723.
14. Esau CC, Monia BP. 2007. Therapeutic potential for microRNAs. Adv Drug Deliv Rev 59:101-114.
15. Guo P, Coban O, Snead NM, Trebley J, Hoeprich S, Guo S, Shu Y. 2010. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev 62:650-666.
16. Carthew RW, Sontheimer EJ. 2009. Origins and mechanisms of miRNAs and siRNAs. Cell 136:642-655.
17. Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A. 2011. MiRNA replacement therapy through PEI-mediated in vivo delivery of miR-145 or miR-33a in colon carcinoma. Cancer Res 71:5214-5224.
18. Wang W, Wu F, Fang F, Tao Y, Yang L. 2008. Inhibition of invasion and metastasis of hepatocellular carcinoma cells via targeting RhoC in vitro and in vivo. Clin Cancer Res 14:6804-6812.
19. Broderick JA, Zamore PD. 2011. MicroRNA therapeutics. Gene Ther 18:1104-1110.
20. Bader AG, Brown D, Winkler M. 2010. The promise of microRNA replacement therapy. Cancer Res 18:7027-7030.
21. Rooij EV, Purcell AL, Levin AA. 2012. Developing microRNA therapeutics. Circ Res 110:496-507.
22. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ. 2008. The Let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7:759-764.
23. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. 2011. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19:1116-1122.
24. Li C, Feng Y, Coukos G, Zhang L. 2009. Therapeutic microRNA strategies in human cancer. AAPS J 11:747-757.
25. Akhtar S, Benter IF. 2007. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 12:3623-332.
26. Weinstein S, Peer D. 2010. RNAi nanomedicines: Challenges and opportunities within the immune system. Nanotechnology 21:232001.
27. Dykxhoorn DM, Palliser D, Lieberman J. 2006. The silent treatment: siRNAs as small molecule drugs. Gene Ther 13:541-552.
28. Cejka D, Losert D, Volker W. 2006. Short interfering RNA (siRNA): Tool or therapeutic? Clin Sci 110:47-58.
29. Laursen MB, Pakula MP, Gao S, Fluiter K, Mook OR, Baas F, Langklaer N. 2010. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst 6:862-870.
30. Pasternak A, Wengel J. 2011. Unlocked nucleic acid-An RNA modification with broad potential. Org Biomol Chem 9:3591-3597.
31. Elmé K, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Orum H, Koch T, Wahlestedt C. 2005. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 33:439-447.
32. Puri N, Wang X, Varma R, Burnett C, Beauchamp L, Batten DM, Young M, Sule V, Latham K, Sendera T, Echeverri C, Sachse C, Magdaleno S. 2008. LNA incorporated siRNAs exhibit lower off-target effects compared to 2′-omethoxy in cell phenotypic assays and microarray analysis. Nucleic Acids Symp Ser 52:25-26.
33. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwinger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl L, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173-178.
34. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vergeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. 2005. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002-1007.
35. Kim JY, Choung S, Lee EJ, Kim YJ, Choi YC. 2007. Immune activation by siRNA/liposome complexes in mice is sequence-independent: Lack of a role for Toll-like receptor 3 signaling. Mol Cells 24:247-254.
36. Judge A, MacLachlan I. 2007. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 19:111-124.
37. Sioud M. 2007. RNA interference and innate immunity. Adv Drug Deliv Rev 59:153-163.
38. Sledz CA, Holko M, De Veer, MJ, Silverman RH, Williams BRG. 2003. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5:834-839.
39. Robbins M, Judge A, MacLachlan I. 2009. siRNA and innate immunity. Oligonucleotides 19:89-102.
40. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J. 2005. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23:709-717.
41. Marques JT, Williams BRG. 2005. Activation of the mammalian immune system by siRNAs. Nat Biotechnol 23:1399-1405.
42. Wilson C, Keefe AD. 2006. Building oligonucleotide therapeutics using non-natural chemistries. Curr Op Chem Biol 10:607-14.
43. Behlke MA. 2008. Chemical modification of siRNAs for in vivo use. Oligonucleotides 18:305-319.
44. Yasuda K, Ogawa Y, Yamane I, Nishikawa M, Takakura Y. 2004. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways. J Leukoc Biol 77:71-79.
45. Burchard J, Jackson AL, Malkov V, Needham RHV, Tan Y, Bartz SR, Dai H, Sachs AB, Linsley PS. 2009. MicroRNA-like off-target transcript regulation by siRNAs is species specific. RNA 15:308-315.
46. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS. 2006. Widespread siRNA off-target transcript silencing mediated by seed region sequence complementarity. RNA 12:1179-1187.
47. Dharmacon Technology Review. 2006. Off-target effects: Disturbing the silence of RNA interference (RNAi). 00082.
48. Shim MS, Kwon YJ. 2010. Efficient and targeted delivery of siRNA in vivo. FEBS J 277:4814-4827.
49. Singh SK, Hajeri PB. 2009. siRNAs: Their potential as therapeutic agents-Part II. Methods of delivery. Drug Discov Today 14:859-865.
50. Xia H, Mao Q, Paulson HL, Davidson BL. 2002. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20:1006-1010.
51. Barton GM, Medzhitov R. 2002. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci U S A 99:14943-14945.
52. Brummelkamp TR, Bernards R, Agami R. 2002. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243-247.
53. Cunningham AP, Andrews LG, Tollefsbol TO. 2007. Retrovirus-mediated RNA interference. Methods Mol Biol 405:39-46.
54. De Fougerolles AR. 2008. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 19:125-132.
55. Manjunath, N, Dykxhoorn DM. 2010. Advances in synthetic siRNA delivery. Discov Med 9:418-430.
56. Gao K, Huang L. 2008. Nonviral methods for siRNA delivery. Mol Pharm 6:651-658.
57. Tao W, Davide JP, Mingmei Cai, Guo-Jun Zhang, Victoria J South, Andrea Matter, Bruce Ng, Ye Zhang, Laura Sepp-Lorenzino. Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Mol Ther 18:1657-1666.
58. Pulford B, Reim N, Bell A, Veatch J, Foster G, Bender H, Meyerett C, Hafeman S, Michel B, Johnson T, Wyckoff AC, Miele G, Julius C, Kranich J, Schenkel A, Dow S, Zabel MD. 2010. Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrPC on neuronal cells and PrPRES in infected cell cultures. PLoS One 5:e11085.
59. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader A. 2010. Development of a lung cancer therapeutic based on the tumor suppressor MicroRNA-34. Cancer Res 70:5923-5930.
60. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. 2010. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 70:3687-3696.
61. Arum CJ, Kodama Y, Rolim N, Wideroe M, Anderssen E, Viset T, Otterlie M, Lundgren S, Chen D, Zhao CM. 2010. A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma. World J Urol 28:479-485.
62. Hauser PV, Pippin JW, Kaiser C, Krofft RD, Brinkkoetter PT, Hudkins KL, Kerjaschki D, Reiser J, Alpers CE, Shankland SJ. 2010. Novel siRNA delivery system to target podocytes in vivo. PLoS One 5:e9463.
63. Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, Gilbert R, Liu FF. 2010. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 77:253-260.
64. Martimprey H, Bertrand JR, Malvy C, Couvreur P, Vauthier C. 2010. New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma. Pharm Res 27:498-509.
65. Noh SM, Park MO, Shim G, Han SE, Le HY, Huh JH, Kim MS, Choi JJ, Kim K, Kwon IC, Kim JS, Baek KH, Oh YK. 2010. Pegylated poly-l-arginine derivatives of chitosan for effective delivery of siRNA. J Control Release 145:159-164.
66. Ofek P, Fischer W, Calderón M, Haag R, Satchi-Fainaro R. 2010. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J 24:3122-3134.
67. Merkel OM, Mintzer MA, Librizzi D, Samsonova O, Dicke T, Sproat B, Garn H, Barth PJ, Simanek EE, Kissel T. 2010. Triazine dendrimers as nonviral vectors for in vitro and in vivo RNAi: The effects of peripheral groups and core structure on biological activity. Mol Pharm 7:969-983.
68. Alshamsan A, Hamdy S, Samuel J, El-Kadi AOS, Lavasanifar A, Uiudag H. 2010. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 31:1420-1428.
69. Lu W, Zhang G, Zhang R, Flores LG, 2nd, Huang Q, Gelovani JG, Li C. 2010. Tumor site-specific silencing of NF-κB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res 70:3177-3188.
70. Chen Q, Butler D, Querbes W, Pandey RK, Ge P, Maier MA, Zhang L, Rajeev KG, Nechev L, Kotelqinski V, Manoharan M, Sah DW. 2010. Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J Control Release 144:227-232.
71. Kim SW, Kim NY, Choi YB, Park SH, Yang JM, Shin S. 2010. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Control Release 143:335-343.
72. Laursen MB, Pakula MM, Gao S, Fluiter K, Mook OR, Bass F, Langklaer N, Wengel SL, Wengel J, Kjems J, Bramsen JB. 2010. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst 6:862-870.
73. Wu JT, Han B-M, Yu SQ, Wang HP, Xia SJ. 2010. Androgen receptor is a potential therapeutic target for bladder cancer. Urology 75:820-827.
74. Wu Y, Wang W, Chen Y, Huang K, Shuai X, Chen Q, Li X, Lian G. 2010. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomed 5:129-136.
75. Lee JW, Tutela JP, Zoumalan RA. 2010. Inhibition of smad3 expression in radiation-induced fibrosis using a novel method for topical transcutaneous gene therapy. Arch Otolaryngol Head Neck Surg 136:714-719.
76. Suda T, Liu D. 2007. Hydrodynamic gene delivery: Its principles and applications. Mol Ther 15:2063-2069.
77. Ichim TE, Li M, Qian H, Popov IA, Rycerz K, Zheng X, White D, Zhong R, Min WP. 2004. RNA interference: A potent tool for gene-specific therapeutics. Am J Transplant 8:1227-1236.
78. Aigner A. 2006. Gene silencing through RNA interference (RNAi) in vivo: Strategies based on the direct application of siRNAs. J Biotechnol 124:12-25.
79. Herweijer H, Wolff JA. 2007. Gene therapy progress and prospects: Hydrodynamic gene delivery. Gene Ther 14:99-107.
80. Nagy AH. 2006. Clinical study with hydrodynamic gene delivery into hepatocytes in humans. 9th Annual Meeting of America Society Gene Therapy, May 31-June 4, 2006, Baltimore, Maryland.
81. Lewis, DL, Wolff JA. 2007. Systemic siRNA delivery via hydrodynamic intravascular injection. Adv Drug Del Rev 59:115-123.
82. Oh YK, Park TG. 2009. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 61:850-862.
83. Wu SY, McMillan NAJ. 2009. Lipidic systems for in vivo siRNA delivery. AAPS J 11:639-652.
84. MacLachlan I. 2008. Liposomal formulations for nucleic acid delivery. In Antisense drug technology: Principles, strategies, and applications; Crooke ST, Ed. CRC Press, New York, NY. pp 237-270.
85. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schimandt, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. 2006. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 5:1708-1713.
86. Garbuzenko OB, Saad M, Betigeri S, Zhang M, Vetcher AA, Soldatenkov VA, Reimer DC, Pozharov PV, Minko T. 2008. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res 26:382-394.
87. Sioud M, Sørensen DR. 2003. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 312:1220-1225.
88. Kim WJ, Kin SW. 2009. Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res 26:657-666.
89. Liu Y, Huang L. 2010. Designer lipids advanced systemic siRNA delivery. Mol Ther 18:669-670.
90. Tseng Y, Mozumdar S, Huang L. 2009. Lipid-based systemic delivery of siRNA. Adv Drug Del Rev 61:721-731.
91. Ma B, Zhang S, Jiang H, Zhao B, Lv H. 2007. Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J Control Release 123:184-194.
92. Lv H, Zhang S, Wang B, Cui S, Yan J. 2006. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 10:100-109.
93. Santel A, Keil O, Giese K, Kaufmann J. 2010. siRNA delivery: The atuPLEX technology for therapeutic siRNa delivery in oncology. Drug Delivery Tech 10:54-57.
94. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Loffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J. 2006. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 13:1222-1234.
95. Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Dirieux B, Roder N, Loffler K, Lange C, Fechtner M, Mopert K, Sisch G, Dames S, Arnold W, Jochims K, Giese K, Wiedenmann B, Scholz A, Kaufman J. 2008. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68:9788-9798.
96. Chen JL, Wang H, Gao JQ, Chen HL, Liang WQ. 2007. Liposomes modified with polycation used for gene delivery: Preparation, characterization and transfection in vitro. Int J Pharm 343:255-261.
97. Chen Y, Zhu X, Zhang X, Liu B, Huang L. 2010. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 18:1650-1656.
98. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DWY, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt M, Jayaram M, Kazem M, Maier MA, Srinivasulu M, Weistein MJ, Chen Q. 2010. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28:172-176.
99. Zimmermann TS, Lee ACH, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, MacClintock K, Nechev LV, Palmer LR, Racie T, Seiffert IR, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Weat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlochher HP, MacLachlan I. 2006. RNAi-mediated gene silencing in non-human primates. Nature 441:111-114.
100. Judge AD, Robbins M, Tavakoli T, Levi J, Hu L, Fronda A, Ambegia E, McClintock K, MacLachlan I. 2009. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119:661-673.
101. Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, Qin J, Cantley W, Qin LL, Racie T, Frank-Kamenestky M, Yip KN, Alvarez R, Sah DW, de Fougerolles A, Fitzgerald K, Koteliansky V, Akinc A, Langer R, Anderson DG. 2010. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A 107:1864-1869.
102. Fulmer T. 2010. Curiously strong lipidoids. SciBX 3:1-2.
103. De Martimprey H, Vauthier C, Malvy C, Couvreur P. 2009. Polymer nanocarriers for the delivery of small fragments of nucleic acids: Oligonucleotides and siRNA. Eur J Pharm Biopharm 71:490-504.
104. Azzam T, Domb J. 2004. Current developments in gene transfection agents. Curr Drug Deliv 1:65-193.
105. He CX, Tabata Y, Gao JQ. 2010. Non-viral gene delivery carriers and its three-dimensional transfection system. Int J Pharm 386:232-242.
106. Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. 2011. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm 77:438-449.
107. Merkel OM, Beyerle A, Librizzi D, Pfestroff A, Behr, TM, Sproat B, Barth, PJ Kissel T. 2009. Nonviral siRNA delivery to the lung: Investigation of PEG-PEI polyplexes and their in vivo performance. Mol Pharm 6:1246-1260.
108. Koo H, Jin Gw, Kang H, Lee Y, Nam K, Zhe BC, Park JS. 2010. Biodegradable branched poly(ethylenimine sulfide) for gene delivery. Biomaterials 31:988-997.
109. Kloeckmer J, Wagner E, Ogris M. 2006. Degradable gene carriers based on oligomerized polyamines. Eur J Pharm Sci 29:414-425.
110. Polyplus Transfection. 2009. jetPEI in vitro DNA transfection protocol. Accessed August 20, 2012, at: http://www.polyplustransfection.com/wpcontent/uploads/2009/08/CPT_101_jetPEI_vN.pdf.
111. Hanai K, Takeshita F, Honma K, Nagahara S, Maeda M, Minakuchi Y, Sano A, Ochiya T. 2006. Atelocollagen-mediated systemic dds for nucleic acid medicines. Ann N Y Acad Sci 1082:9-17.
112. Inaba S, Nagahara S, Makita N, Tarumi Y, Ishimoto T, Matsuo S, Kadomatsu K, Takei Y. 2012. Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther 20:356-366.
113. Sano A, Maeda M, Nagahara S, Ochiya T, Honma K, Itoh H, Miyata T, Fujioka K. 2003. Atelocollagen for protein and gene delivery. Adv Drug Deliv Rev 5:1651-1677.
114. Foorotan SS, Bao ZZ, Foorotan FS, Kamalian L, Zhang Y, Bee A, Foster CS, Ke Y. 2010. Atelocollagen-delivered siRNA targeting the FABP5 gene as an experimental therapy for prostate cancer in mouse xenografts. Int J Oncol 36:69-76.
115. Jere D, Jiang HL, Kim YK, Arote R, Choi YJ, Yun CH, Cho MH, Cho CS. 2009. Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells. Int J Pharm 378:194-200.
116. Saranya N, Moorthi A, Saravanan S, Pandima Devi M, Selvamurugan N. 2011. Chitosan and its derivatives for gene delivery. Int J Biol Macromol 48:234-238.
117. Liu X, Howard KA, Dong M, Andersen MO, Rahbek UL, Johnsen MG, Hansen OC, Besenbacher Kjems J, Kjems F. 2007. The Influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 28:1280-1288.
118. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO, Hovgaard MB, Schmithz A, Myengaard JR, Besenbacher F, Kjems J. RNA interference in vitro and in vivo using a chitosan/siRNA nanoparticle system. Mol Ther 14:476-484.
119. Sato T, Ishii T, Okahata Y. 2001. In vitro gene delivery mediated by chitosan. Effect of pH, serum, and molecular mass of chitosan on the transfection efficiency. Biomaterials 22:2075-2080.
120. Rudzinski WE, Aminabhavi TM. 2010. Chitosan as a carrier for targeted delivery of small interfering RNA. Int J Pharm 399:1-11.
121. Kim Tae-Hee, Jiang Hu-Lin, Dhananjay Jere, Park In-Kyu, Cho Myung-Haing, Nah Jae-Woon, Choi Yun-Jaie, Toshihiro Akaike, Cho Chong-Su. 2007. Chemical modification of chitosan as a gene carrier in vitro and in vivo. Prog Polym Sci 32:726-753.
122. Cun D, Jensen DK, Maltesen MJ, Bunker M, Whiteside P, Scurr D, Foged C, Nielsen HM. 2011. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: Quality by design optimization and characterization. Eur J Pharm Biopharm 77:26-35.
123. Du J, Sun Y, Shi QS, Liu PF, Zhu MJ, Wang CH, Du LF, Duan YR. 2012. Biodegradable nanoparticles of mPEG-PLGA-PLL triblock copolymers as novel non-viral vectors for improving siRNA delivery and gene silencing. Int J Mol Sci 13:516-533.
124. Tahara K, Yamamoto H, Hirashima N, Kawashima Y. 2010. Chitosan-modified poly(d, l-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur J Pharm Biopharm 74:421-426.
125. Yuan X, Shah BA, Kotadia, NK, Li J, Gu H, Wu Z. 2010. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res 27:1285-1295.
126. Liang GF, Zhu YL, Sun Bo, Hu FH, Tian T, Li SC, Xiao ZD. 2011. PLGA-based gene delivering nanoparticle enhance suppression effect of miRNA in HePG2 cells. Nanoscale Res Lett 6:447.
127. Jensen DK, Jensen LB, Koocheki S, Bengtson L, Cun D, Nielsen HM, Foged C. 2010. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Control Release 157:141-148.
128. Lewis D. 2010. Dynamic polyconjugates (DPC) technology: An elegant solution to the siRNA delivery problem. Accessed August 20, 2012 at: http://www.arrowheadresearch.com/sites/default/files/udocs/Arrowhead_Research_Corporation-DPC_Technology_White_Paper.pdf.
129. Mirus Corporation. Dynamic polyconjugates-siRNA delivery system. Accessed 20 August 2012, at: http://www.biotechprofiles.com/companyfiles/madisonnetwork/aa3cafcd980640428bdecc680afa0ae4.pdf.
130. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, Bertin SL. 2007. Dynamic polyonjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A 104:12982-12987.
131. Wang J, Lu Z, Wientjes MG, Au JL. 2010. Delivery of siRNA therapeutics: Barriers and carriers. AAPS J 12:492-503.
132. Mark ED. 2009. The first targeted delivery of siRNA in humans via self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm 6:659-668.
133. Patil Y, Panyam Y. 2009. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm 367:195-203.
134. Nguyen J, Steele TWJ, Merkel O, Reul R, Kissel T. 2008. Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy. J Control Release 132:243-251.
135. Katas H, Cevher E, Alpar HO. 2009. Preparation of polyethyleneimine incorporated poly(d, l-lactide-co-glycolide) nanoparticles by spontaneous emulsion diffusion method for small interfering RNA delivery. Int J Pharm 369:144-154.
136. Gao JQ, Zhao QQ, Lv TF, Shuai WP, Zhou J, Tang GP, Liang WQ, Tabata Y, Hu YL. 2010. Gene-carried chitosan-linked-PEI induced high gene transfection efficiency with low toxicity and significant tumor-suppressive activity. Int J Pharm 387:286-294.
137. Rojanarata T, Opanasopit P, Techaarpornkul S, Ngawhirunpat T, Ruktanonchai U. 2008. Chitosan-thiamine pyrophosphate as a novel carrier for siRNA delivery. Pharm Res 25:2807-2814.
138. Andersen MØ, Howard KA, Paludan SR, Besenbacher F, Kjems J. 2008. Delivery of siRNA from lyophilized polymeric surfaces. Biomaterials 29:506-512.
139. Koping-Hoggard M, Tubulejas I, Guan H, Edwards K, Nilsson M, Varum KM, Artursson P. 2001. Chitosan as a nonviral gene delivery system. Structure property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther 8:1108-1121.
140. Dehousse V, Garbacki N, Jaspart S, Castagne D, Piel G, Colige A, Evrard B. 2010. Comparison of chitosan/siRNA and trimethylchitosan/siRNA complexes behaviour in vitro. Int J Biol Macromol 46:342-349.
141. Techaarpornkul S, Wongkupasert S, Opanasopit P, Apirakaramwong A, Nunthanid J, Ruktanonchai U. 2010. Chitosan-mediated siRNA delivery in vitro: Effect of polymer molecular weight, concentration and salt forms. AAPS PharmSciTech 11:64-72.
142. Wong K, Sun G, Zhang X, Dai H, Liu Y, He C, Leong K. 2006. PEI-g-chitosan, a novel gene delivery system with transfection efficiency comparable to polyethylenimine in vitro and after liver administration in vivo. Bioconjug Chem 17:152-158.
143. Höbel S, Koburger I, John M, Czubayko F, Hadwiger P, Vornlocher HP, Aigner A. 2010. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with bevacizumab. J Gene Med 12:287-300.
144. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC. 2004. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32:e149.
145. Watanabe K, Harada-Shiba M, Suzuki A, Gokuden R, Kurihara R, Sugao Y, Mori T, Katayama Y, Niidome T. 2009. In vivo siRNA delivery with dendritic poly(l-lysine) for the treatment of hypercholesterolemia. Mol Biosyst 5:1306.
146. Kim E, Shim G, Kim K, Kwon IC, Oh YK, Shim CK. 2009. Hyaluronic acid complexed to biodegradable poly l-arginine for targeted delivery of siRNAs. J Gene Med 11:791-803.
147. Jere D, Xu C-X, Arote R, Yun CH, Cho MH, Cho CS. 2008. Poly([beta]-amino ester) as a carrier for si/shRNA delivery in lung cancer cells. Biomaterials 29:2535-2547.
148. Silva CM, Ribeiro AJ, Figueiredo IV, Gonçalves AR, Veiga F. 2006. Alginate microspheres prepared by internal gelation: Development and effect on insulin stability. Int J Pharm 311:1-10.
149. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas. 2010. An evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-1070.
150. Garzon R, Calin GA, Croce CM. 2009. MicroRNAs in cancer. Annu Rev Med 60:167-179.
151. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. 2005. Silencing of microRNAs in vivo with antagomirs. Nature 438:685-689.
152. Meade BR, Dowdy SF. 2007. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 59:134-140.
153. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B. 2003. Cell-penetrating peptides. J Biol Chem 278:585-590.
154. Simeoni F, Morris MC, Heitz F, Divita G. 2003. Insight into the mechanism of the peptide-based gene delivery system MPG: Implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 31:2717-2724.
155. Manickam DS, Oupický D. 2006. Multiblock reducible copolypeptides containing histidine-rich and nuclear localization sequences for gene delivery. Bioconjug Chem 17:1395-1403.
156. Rahbek UL, Howard KA, Oupicky D, Manickam DS, Dong M, Nielsen AF, Hansen TB, Besenbacher F, Kjems J. 2008. Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides. J Gene Med 10:81-93.
157. Moschos SA, Williams AE, Lindsay MA. 2007. Cell-penetrating-peptide-mediated siRNA lung delivery. Biochem Soc Trans 35:807-810.
158. Rajappa M, Saxena P, Kaur J. 2010. Ocular angiogenesis: Mechanisms and recent advances in therapy. Adv Clin Chem 50:103-121.
159. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, Hackett SF, Zinnen S, Kossen K, Fosnaugh K, Vargeese C, Gomez A, Bouhana K, Aitchison R, Pavco P, Campochiario PA. 2005. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 13:225-234.
160. Kaiser PK, Symons RCA, Shah SM, Quinlan EJ, Tabandeh H, Do DV, Reisen G, Lockridge JA, Short B, Guerciolini R, Nguyen QD, Sirna-027 Investigators. 2010. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 150:33-39.
161. Singerman L. 2009. Combination therapy using the small interfering RNA bevasiranib. Retina 29:S49-S50.
162. ClinicalTrials.gov. Accessed, at: http://clinicaltrials.gov/.
163. OPKO Ophthalmics. Accessed, 20 August 2012, at: http://www.opko.com/research/?doc=ophthalmics.
164. Moschos SA, Jones SW, Perry MM, Williams AE, Erjefalt JS, Turner JJ, Barnes PJ, Sproat BP, Gait MJ, Lindsay MA. 2007. Lung delivery studies using siRNA conjugated to TAT (48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 18:1450-1459.
165. DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, Meyers R, Gollob J, Vaishnaw A. 2010. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A 107:8800-8805.
166. Büchele T. 2003. Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide) review of preclinical and clinical results. Onkologie 26:60-69.
167. Tekmira Pharmaceuticals. 2010. Accessed, August 20, 2012 at: http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=534312.
168. Sah D. 2011. Phase I safety, pharmacokinetic and pharmacodynamics results for ALN-TTR01. VIIIth International Symposium on FAP November 20-22, 2011, Kumamoto, Japan.